[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"measles\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:measles":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,145,166,195,215,242],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100624186","phase-3-a-study-on-the-immune-response-and-safety-of-an-investigational-combined-measles-mumps-rubella-and-varicella-vaccine-when-administered-as-intramuscular-injection-to-healthy-children-15-months-to-6-years-of-age-100624186",false,"NCT07406360","A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age","Inclusion Criteria:\n\n* Participants' parent(s)\u002Flegally acceptable representative(s) (LAR(s)) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n* Written or witnessed\u002Fthumb printed informed consent obtained from the participants parent(s)\u002FLAR(s) prior to performance of any study specific procedure.\n* Informed assent obtained from the participants in line with local rules and regulations.\n* Healthy participants as established by medical history and clinical examination at screening.\n\nFor countries where the second dose of measles, mumps, rubella, and varicella vaccination is administered between 4 and 6 years of age:\n\n* A male or female participant between and including 4 and 6 years of age at the time of the study intervention administration, and in accordance with local regulations.\n* Participant who previously received a first dose of varicella-containing vaccine in the second year of life.\n* Participant who previously received a first dose of measles, mumps, rubella-containing vaccine in the second year of life.\n\nFor other countries:\n\n* A male or female participant between and including 15 months to 6 years of age at the time of study intervention administration, and in accordance with local regulations.\n* Participant who previously received a first dose of varicella-containing vaccine in the second year of life, or earlier at 11 months of age in accordance with national vaccination schedule following official recommendation, at least 3 months before study entry.\n* Participant who previously received a first dose of measles, mumps, rubella-containing vaccine in the second year of life, or earlier at 11 months of age in accordance with national vaccination schedule following official recommendation, at least 1 month before study entry.\n\nExclusion Criteria:\n\nMedical conditions\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions, including hypersensitivity to neomycin or, gelatin.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Hypersensitivity to latex.\n* Unstable chronic conditions as determined by medical history and physical examination.\n* Major congenital defects, as assessed by the investigator.\n* History of measles, mumps, rubella, or varicella\u002Fzoster disease, as evaluated by the investigator.\n* Recurrent history or uncontrolled neurological disorders or any neuroinflammatory, congenital neurological conditions, encephalopathies, or seizures.\n* History of febrile seizures, for participant under 4 years of age.\n* Active untreated tuberculosis.\n* Condition that, in the judgement of the investigator, would make intramuscular injection unsafe.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.\n\nPrior\u002FConcomitant therapy\n\n* Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the dose of study intervention, or their planned use during the study period.\n* Administration of immunoglobulins or other blood products or plasma derivates during the period starting 90 days before the study intervention or planned administration during the study period.\n* Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune-modifying treatments at any time up to the end of the study.\n\n  * Up to 90 days prior to the study interventions administration: systemic corticosteroid.\n  * Up to 180 days prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy, monoclonal antibodies, antitumoral medication.\n* Previous vaccination with a second dose of varicella containing vaccine or measles, mumps, rubella-containing vaccine.\n* Use of salicylates or salicylate-containing products or its planned use during the period of 6 weeks following study intervention administration.\n* Planned administration\u002Fadministration of a vaccine not foreseen by the study protocol in the period starting 30 days before the dose and ending 43 days after the dose of study intervention administration, with the exception of:\n* Inactivated influenza vaccine, which may be given at any time during the study and administered at a different location than the study intervention, and\n* Diphtheria, tetanus, acellular pertussis-containing vaccines may be administrated according to the local immunization practices of each participating country. It has to be administered on the same day as the study intervention administration at a different location. However, other than protocol-specified DTaP brand and diphtheria, tetanus, whole cell pertussis-containing vaccines are not allowed.\n\nIf emergency mass vaccination for an unforeseen public health threat is recommended and\u002For organized by public health authorities outside the routine immunization program, the time period described above can be reduced provided it is used according to the local governmental recommendations and sponsor is notified.\n\nPrior\u002FConcurrent clinical study participation\n\n• Concurrently participating in another clinical study, at any time during the study period,\n\nOther exclusion criteria\n\n* Any study personnel's immediate dependents, family, or household members.\n* Child in care.\n* Participants with the following high-risk individuals in their household:\n\n  * Immunocompromised individuals.\n  * Pregnant women without documented history of varicella.\n  * Newborn infants of mothers without documented history of varicella.\n  * Newborn infants born \\\u003C28 weeks of gestation.",true,"ALL","15 Months","6 Years",{"count":21,"type":22},1209,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).",[28],"Measles",[28,30,31,32,33,34],"Mumps","Rubella","Varicella","Safety","Immunogenicity","NOT_YET_RECRUITING","2026-02-06",{"date":38,"type":39},"2026-02-12","ACTUAL",{"date":41,"type":22},"2026-04-13",{"date":43,"type":22},"2028-06-22",{"name":45,"class":46},"GlaxoSmithKline","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":115,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":144},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":57,"type":22},10000,"OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,28,30,31,83,84,85,86,87,32,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":136,"type":39},"2026-01-22",{"date":138,"type":39},"2025-12-18",{"date":140,"type":22},"2027-09-30",{"name":142,"class":143},"Institut Pasteur du Cambodge","OTHER",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100618994","the-five-year-antibody-persistence-after-immunization-with-ipv-mmr-and-hepa-l-vaccines-100618994","NCT07338851","the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","Evaluation on the Persistence of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell), Combined Live Attenuated Measles, Mumps and Rubella Vaccine and Freeze-dried Live Attenuated Hepatitis A Vaccine in Chinese Children: Up to 5 Years of Follow-up","Inclusion Criteria:\n\n* Participants in the NCT04638985 or NCT04636827, and who have completed the vaccination of designated batch numbers of sIPV, MMR or HepA-L vaccines;\n* The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months.\n* The informed consent form shall be signed by the participant or his\u002Fher legal guardian and dated.\n\nExclusion Criteria:\n\n* None.",{"count":153,"type":22},600,"This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.",[156,28,31,30,88],"Polio","2026-01-04",{"date":134,"type":39},{"date":160,"type":22},"2026-01-30",{"date":162,"type":22},"2027-12-31",{"name":164,"class":46},"China National Biotec Group Company Limited",6,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100601619","prospective-clinical-registry-for-evaluation-of-exanthematous-infections-and-coinfections-100601619","NCT07112846","Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections","CRIUS","Inclusion Criteria:\n\nIndividuals from newborns (zero years old) to 18 years of age, of both sexes.\n\nSuspected individuals with the following criteria:\n\nMeasles: Presenting fever and rash associated with cough and\u002For runny nose and\u002For conjunctivitis, regardless of age or vaccination status;\n\nRubella: Presenting fever, rash, and lymphadenopathy, regardless of age or vaccination status;\n\nDengue and Chikungunya: Presenting myalgia, arthralgia, headache, retro-orbital pain, nausea, vomiting, rash, petechiae, positive tourniquet test, or leukopenia and\u002For lymph node enlargement;\n\nIndividuals who, meeting the above criteria, underwent sample collection for viral panel testing for the differential diagnosis of exanthematous diseases.\"\n\nExclusion Criteria:\n\n\\-","18 Years",{"count":175,"type":22},830,"Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an extremely concerning scenario from both epidemiological and healthcare perspectives. In addition to this, the reemergence of childhood exanthematous diseases in several countries, including Brazil, is alarming and occurs due to declining vaccination coverage and increased migratory movements. These diseases present overlapping clinical symptoms, and their differential diagnosis is often challenging, which, in a context of dengue and Chikungunya epidemics like the current one, may lead to underreporting of diseases such as measles and rubella. This project aims to build a prospective registry of the occurrence of dengue, Chikungunya, measles, and rubella in various healthcare centers in Brazil, in order to better understand the epidemiological scenario, identify clinical variables associated with different diagnoses, and describe healthcare bottlenecks that may hinder proper reporting and identification of these diseases.",[178,179,62,28,31],"Exanthema","Dengue Fever",[181,182,62,183,184,185],"exanthema","dengue fever","measles","rubella","epidemiology","2025-08-01",{"date":188,"type":39},"2025-08-08",{"date":190,"type":22},"2025-09-01",{"date":192,"type":22},"2026-06-30",{"name":194,"class":143},"Hospital Israelita Albert Einstein",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100505404","clinical-diagnostic-performance-evaluation-of-a-measles-rapid-test-in-senegal-100505404","NCT05860920","Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in Senegal","Clinical Diagnostic Performance Evaluation of an Anti-Measles IgM Lateral Flow Immunochromatographic Assay for Outbreak Detection and Surveillance in Senegal","Inclusion Criteria:\n\nPatients presenting at study sites:\n\n* For whom confirmatory diagnostic testing is currently indicated as per the national surveillance protocol\n* With clinical signs and symptoms consistent with the WHO suspected measles case definition including: History of fever, or observed fever (\\>37.5C) at presentation and a (non-vesicular) maculopapular rash; or clinically suspected measles\n* ≤ 28 days after the onset of a rash\n* Who if \\\u003C18 years of age, have written, informed consent from their legal guardian (and verbally assent if more than 7 years old)\n* Who if more than 18 years, give written, informed consent\n\nExclusion Criteria:\n\n* Withdrawal of consent or assent as described above, at any time.\n* Unsuccessful venous blood sampling after a maximum of 3 attempts, or a serum sample is no longer available for any reason.\n* Clinical signs or symptoms requiring immediate referral\u002Ftransfer of the patient to another site or centre, and\u002For for whom participation would involve a delay of urgent clinical interventions or investigations (i.e. potential inclusion of patients requiring immediate clinical management should be deferred until the patient is clinically stable).\n* Clinical signs or symptoms that may be exacerbated by blood draw or upper respiratory sampling (e.g. stridor or severe respiratory distress)\n\nParticipants who meet the inclusion criteria should be included in the study but without oral fluid sampling if:\n\n* They have a sore mouth or gums that would be exacerbated with oral fluid sampling\n* They are significantly dehydrated and the mouth is very dry\n* They refuse or are not able to cooperate with oral fluid sampling",{"count":203,"type":22},850,"The goal of this study is to measure the accuracy of a new measles rapid test when used in clinical health centres in several regions of Senegal. The rapid test will be used to test patients for measles who attend the participating health centres with signs and symptoms suggestive of measles infection. The rapid test can be used with a drop of blood from a finger, or oral fluid sampled with a swab rubbed over the gums. The rapid test will be compared to the standard methods of diagnosis in the laboratory using blood samples and oral or throat samples taken for surveillance purposes.\n\nThe main questions the study aims to answer are:\n\n1. What is the accuracy of the rapid test when used with capillary blood (a drop of blood from the finger tip) in health centres by non-laboratory health professionals?\n2. What is the accuracy of the rapid test when used with oral fluid by non-laboratory health professionals?\n\nIn addition to measuring the accuracy of the test, data will also be collected on whether the test is easy and practical to use and how best to record the results.",[28],"2025-05-08",{"date":208,"type":39},"2025-05-13",{"date":210,"type":22},"2025-07",{"date":212,"type":22},"2026-06",{"name":214,"class":143},"Institut Pasteur de Dakar",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":16,"sex":17,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":144},"100578787","phase-3-non-interference-study-of-mr-and-yellow-fever-vaccines-among-bangladeshi-infants-aged-9-12-months-100578787","NCT06815835","Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","A Prospective, Randomized, Parallel, Three-arm, Open-label, Clinical Trial to Evaluate the Immunological Non-interference of Measles and Rubella Vaccine (Live) I.P. (Freeze Dried) of M\u002Fs. Zydus Lifesciences Ltd. With Yellow Fever Vaccine Administered to Bangladeshi Healthy Infants Aged 9-12 Months","Inclusion Criteria:\n\n* The participant must satisfy all the following criteria to be eligible for enrolment:\n* Healthy infant participants of either gender aged\\* 9 to 12 months at the time of enrollment\n* Participants should be in good health as determined by the medical history and physical examination based on the clinical judgment of the investigator\n* No previous history of vaccination against measles, rubella, or Yellow fever\n* Written informed consent from the participant's parent\u002Fguardian\n* Participant's parent\u002Fguardian literate enough to fill the diary card \\*Age calculated as per completed month\n\nExclusion Criteria:\n\n* Participants positive for serological markers against Dengue and\u002For Japanese Encephalitis infections\n* History of hypersensitivity reaction to any component of the study vaccines including egg and chicken proteins\n* History of hypersensitivity reaction to neomycin\n* History of laboratory-confirmed or suspected measles, rubella, or Yellow fever in the past\n* Participant exposed# to measles, rubella, or Yellow fever virus within the past 30 days\n* Fever of any origin or infectious disorder of 3 days or more within the past month\n* Febrile illness (axillary temperature ≥37.5°C) at the time of enrollment\n* History of any vaccination within the past month\n* Clinically significant systemic disorders such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, haematological, immunological, or metabolic disorder\n* Confirmed or suspected immunosuppressive or immunodeficiency disorder; or participants on any immunosuppressive or immunostimulant therapy\n* Known case of thrombocytopenia or any coagulation disorder, or participants on anticoagulation therapy\n* Participants administered blood, blood-containing products, or immunoglobulins within the last 3 months or planned administration during the study\n* Participant participated in another clinical study in the past 3 months\n* Any other reason for which the investigator feels that the participant should not participate #Close contact (family member or neighbour) with laboratory-confirmed or clinical diagnosis of measles\u002Frubella\u002FYellow fever","9 Months","12 Months",{"count":225,"type":22},1530,[25],"This study will be conducted among 1530 healthy infants of 9 to 12 months of age residing in the Dakshinkhan and Uttarkhan area which is located in Dhaka North City Corporation (DNCC) to enroll the required number of participants. Only infants who have not previously received the MR and YF vaccines will be enrolled. The findings of this study are likely to have a significant impact on vaccine co-administration strategies for campaign and routine immunization programs. The participants will be assigned to one of the three groups by the central computer-generated randomization schedule. The numbers are defined for each arm (Table 1) based on the sample size calculation. A list of infants who did not receive MR and Yellow fever vaccine will be prepared before enrollment by trained study staff (TSS). The TSSs will visit households in the defined study area and ask if the parents\u002Fguardians of infants aged 9-12 months are willing to participate in the study. If they show a willingness to participate, the TSSs will check their vaccination cards (if available) and prepare the list of potentially eligible infants who have not received MR and Yellow fever vaccines based on their vaccination card status. The investigators will collect blood specimens (4-5 ml) at the time of screening (visit-1), to evaluate serological markers of dengue and Japanese Encephalitis infection and for baseline (pre-vaccination) immunological assessment. The investigators will vaccinate seronegative, eligible participants within 24 hours of blood collection. There will be additional three follow-up visits after enrollment and will collect around 3-4 ml blood from each participant during visit 4 (week 6), and visit 5 (week 26) for immunological assessment. Diary cards will be used to collect adverse events (AEs) following immunization (AEFI) data for vaccinated participants (up to 14 days for solicited and 6 weeks for unsolicited AEs). Medically attended adverse events (MAAEs) and data on serious adverse events (SAEs) will be reported during the study. All study updates including AEs and SAEs will be reported to the data safety and monitoring board (DSMB) and sponsor.",[28,31,77],[33,230,231,232,34],"Non-interference","Measles and Rubella","Co-administration","2025-02-06",{"date":235,"type":39},"2025-02-07",{"date":237,"type":22},"2025-04-01",{"date":239,"type":22},"2026-03-31",{"name":241,"class":143},"International Centre for Diarrhoeal Disease Research, Bangladesh",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":16,"sex":250,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":270,"locationsCount":144},"100431567","phase-4-measles-and-bcg-vaccines-for-mother-and-child-100431567","NCT04899765","Measles and BCG Vaccines for Mother and Child","Specific and Non-specific Effects of Measles and BCG Vaccines for Mother and Child","MATVAC","Inclusion Criteria:\n\n* Female women in the fertile age\n* Non-pregnant\n* HIV-negative\n* Living in the BHP HDSS study area\n* Delivered a child that has reached 12 months of age\n* Currently not using contraceptives.\n\nExclusion Criteria:\n\n* Positive pregnancy test\n* Positive HIV test\n* Tuberculosis (previous or current)\n* Immunodeficiency\n* Cancer within the last 2 years\n* Mid-upper-arm-circumference\\\u003C200\n* Acute ongoing infection","FEMALE","15 Years","35 Years",{"count":254,"type":22},2400,[256],"PHASE4","In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other infections: they have beneficial \"non-specific effects\". The investigators have now seen signs that these non-specific effects for children are stronger if their mother has been given the same vaccines.\n\nIn Africa, BCG vaccine is recommended at birth and measles vaccine at 9 months of age. They are not used beyond childhood.\n\nThe investigators will randomize 2400 women to BCG vaccine, measles vaccine, or placebo. The investigators will further randomize their children to an extra early measles vaccine or placebo. The investigators will assess which of the resulting six vaccination schedules are best for women's and children's protection against measles, for the child's immune system, and for general health.\n\nThe project will be the first in the world to investigate the importance of vaccinating women with live vaccines.",[259,28,260,261],"Vaccine Preventable Disease","Mother-Infant Interaction","BCG Vaccination Reaction",[263],"Non-specific effects of vaccines","2024-01-18",{"date":266,"type":39},"2024-01-19",{"date":268,"type":39},"2021-05-20",{"date":162,"type":22},{"name":271,"class":143},"Bandim Health Project"]